Frequency Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference
Frequency Therapeutics, Inc. (Nasdaq: FREQ) announced that CEO David L. Lucchino will present a company overview at the 20th Annual Needham Virtual Healthcare Conference on April 14 at 8:00 a.m. EDT. Investors can access a live webcast of the presentation on Frequency's website, with a replay available after the event. The company focuses on developing medicines that activate progenitor cells to repair damage from degenerative diseases. Its lead product, FX-322, aims to regenerate auditory hair cells for hearing restoration and is under evaluation in ongoing clinical studies.
- None.
- None.
Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced that Chief Executive Officer David L. Lucchino will present a company overview at the 20th Annual Needham Virtual Healthcare Conference.
Mr. Lucchino’s presentation will take place on Wednesday, April 14 at 8:00 a.m. EDT.
A live webcast of the presentation can be accessed on the investors section of Frequency’s website, investors.frequencytx.com. A replay of the presentation will be posted on the Frequency website following the event.
About Frequency Therapeutics
Frequency Therapeutics is a leader in the development of medicines designed to activate progenitor cells within the body to treat degenerative diseases. The Company’s progenitor cell activation (PCA) approach stimulates progenitor cells to create functional tissue with the aim of developing disease modifying therapies. The Company’s lead product candidate, FX-322, is designed to regenerate auditory hair cells to restore hearing function. FX-322 is being evaluated in multiple ongoing clinical studies in patients with sensorineural hearing loss. The Company also is evaluating additional diseases where its PCA approach could create functional tissue, including in a pre-clinical program in multiple sclerosis.
Headquartered in Woburn, Mass., Frequency has an ex-U.S. license and collaboration agreement with Astellas Pharma Inc. for FX-322, as well as additional collaboration and licensing agreements with academic and nonprofit research organizations including Massachusetts Eye and Ear, Mass General Brigham, the Massachusetts Institute of Technology, The Scripps Research Institute and Cambridge Enterprises Limited. For more information, visit www.frequencytx.com and follow Frequency on Twitter @Frequencytx.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210409005033/en/
FAQ
When will Frequency Therapeutics present at the Needham Virtual Healthcare Conference?
Who is presenting for Frequency Therapeutics at the conference?
How can I access the presentation by Frequency Therapeutics?
What is FX-322 developed by Frequency Therapeutics?
What is the primary focus of Frequency Therapeutics?
